---
title: "3D Bioprinted Human Skin Melanoma Model for High-Throughput Drug Screening"
id: "biorxiv-2-a-three-dimensional-bioprinted-skin-melanoma-model-for-high-throughput-drug"
canonical_url: "https://medichelpline.com/clinical-feed/biorxiv-2-a-three-dimensional-bioprinted-skin-melanoma-model-for-high-throughput-drug"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "bioRxiv (Biomedical Preprints)"
source_url: "https://www.biorxiv.org/content/10.64898/2026.11.06.764888v1?rss=1"
published_at: "2026-11-14T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# 3D Bioprinted Human Skin Melanoma Model for High-Throughput Drug Screening
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/biorxiv-2-a-three-dimensional-bioprinted-skin-melanoma-model-for-high-throughput-drug
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** bioRxiv (Biomedical Preprints)
- **Source URL:** [Original Journal Publication](https://www.biorxiv.org/content/10.64898/2026.11.06.764888v1?rss=1)
- **Published At:** 2026-11-14T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- The investigators developed a **three-dimensional bioprinted** full-thickness human skin construct that incorporates primary human dermal fibroblasts and keratinocytes alongside melanoma tumor-like cell clusters. - The tumor-like aggregates were positioned at the dermal-epidermal interface and covered by a differentiated epidermis cultured at the air-liquid interface, reproducing key structural features of the cutaneous **tumor microenvironment**. - Melanoma cells and fibroblasts were engineered to express red and green fluorescent proteins, respectively, enabling automated confocal imaging to quantify both tumor growth and stromal viability in parallel. - The assay uses a dual-readout strategy that provides an intrinsic counterscreen, allowing investigators to separate **melanoma-selective** cytotoxic effects from nonspecific stromal toxicity. - The platform was implemented in a 96-well bioprinted format compatible with concentration-response testing and high-content, multiplexed analysis for compound libraries. - Using this workflow, the study team identified compounds that selectively reduced melanoma cell viability while largely sparing surrounding stromal cells, demonstrating improved preclinical discrimination of tumor-selective activity. - The authors reported that combining bioprinting, human tissue engineering, and automated imaging produces a scalable approach intended to better recapitulate human skin biology for drug discovery. - The article is a preprint and has not undergone peer review; the source did not report regulatory milestones, detailed assay validation statistics, or clinical translation plans within the abstract.
## Clinical Analysis & Structured Key Points
[](https://www.biorxiv.org/cdn-cgi/content?id=GCAIadB28Jt70T4o9QHGf.3BvcVQ2bxcDBj7wJoWbik-1794771636.3481705-1.2.1.1-wKszn86ewIfJ_uVVAfPBpylOLud_AI7XKwWwLJLLgHsHYH1Tvn9rcQUi78hoEtGN) [Skip to main content](https://www.biorxiv.org/content/10.64898/2026.11.06.764888v1?rss=1#main-content) [![bioRxiv](https://www.biorxiv.org/sites/default/files/biorxiv_article_logo.jpg)](https://www.biorxiv.org/) * [Home](https://www.biorxiv.org/) * [Submit](https://www.biorxiv.org/submit-a-manuscript) * [FAQ](https://www.biorxiv.org/about/FAQ) * [Blog](https://connect.biorxiv.org/news/) * [ALERTS / RSS](https://www.biorxiv.org/content/alertsrss) * [Resources](https://connect.biorxiv.org/resources/) * [About](https://www.biorxiv.org/content/about-biorxiv) * [Channels](https://www.biorxiv.org/content/10.64898/2026.11.06.764888v1?rss=1) * [4D Nucleome](https://connect.biorxiv.org/relate/content/66) * [Academia Sinica](https://connect.biorxiv.org/group/content/38) * [Advances in Genome Biology and Technology (AGBT) General Meeting 2016 #AGBT16](https://connect.biorxiv.org/relate/content/10) * [Albert Einstein College of Medicine](https://connect.biorxiv.org/group/content/4) * [Aligning Science Across Parkinson's (ASAP)](https://connect.biorxiv.org/relate/content/195) * [Allen Institute for Cell Science](https://connect.biorxiv.org/relate/content/71) * [Arc Institute](https://connect.biorxiv.org/relate/content/224) * [Babraham Institute](https://connect.biorxiv.org/relate/content/197) * [BICCN/BICAN](https://connect.biorxiv.org/relate/content/208) * [BioImaging North America](https://connect.biorxiv.org/relate/content/194) * [Biology of Genomes 2016 #BOG16](https://connect.biorxiv.org/relate/content/19) * [Breakthrough Discoveries for Thriving with Bipolar Disorder](https://connect.biorxiv.org/relate/content/236) * [Brown University](https://connect.biorxiv.org/group/content/9) * [California Institute of Technology](https://connect.biorxiv.org/group/content/32) * [Carnegie Mellon University](https://connect.biorxiv.org/group/content/19) * [Case Western Reserve University](https://connect.biorxiv.org/group/content/36) * [Central Oxford Structural Microscopy and Imaging](https://connect.biorxiv.org/relate/content/143) * [Centre for Microbiology and Environmental Systems Science](https://connect.biorxiv.org/relate/content/190) * [Chan Zuckerberg Biohub](https://connect.biorxiv.org/relate/content/121) * [Columbia University](https://connect.biorxiv.org/group/content/27) * [Donders Institute for Brain, Cognition and Behaviour](https://connect.biorxiv.org/relate/content/184) * [DREAM](https://connect.biorxiv.org/relate/content/153) * [Drug Development and Clinical Therapeutics](https://connect.biorxiv.org/relate/content/52) * [ENCODE](https://connect.biorxiv.org/relate/content/177) * [Ernst Strüngmann Institute (ESI) for Neuroscience](https://connect.biorxiv.org/relate/content/211) * [European Molecular Biology Laboratory (EMBL)](https://connect.biorxiv.org/relate/content/159) * [Francis Crick Institute](https://connect.biorxiv.org/relate/content/88) * [Fred Hutchinson Cancer Center](https://connect.biorxiv.org/group/content/28) * [Georgia Institute of Technology](https://connect.biorxiv.org/group/content/20) * [Harvard Program in Therapeutic Sciences](https://connect.biorxiv.org/relate/content/151) * [The Howard Hughes Medical Institute (HHMI)](https://connect.biorxiv.org/relate/content/227) * [Human Cell Atlas](https://connect.biorxiv.org/relate/content/163) * [Human Pangenome Reference Consortium (HPRC)](https://connect.biorxiv.org/relate/content/215) * [IMO Workshop](https://connect.biorxiv.org/relate/content/8) * [Impact of Genomic Variation on Function (IGVF)](https://connect.biorxiv.org/relate/content/214) * [Institut Pasteur](https://connect.biorxiv.org/relate/content/235/channel) * [Institute of Science and Technology Austria](https://connect.biorxiv.org/group/content/12) * [International Human Epigenome Consortium (IHEC)](https://connect.biorxiv.org/relate/content/219) * [International Mouse Phenotyping Consortium (IMPC)](https://connect.biorxiv.org/relate/content/185) * [Iowa State University](https://connect.biorxiv.org/group/content/6) * [Johns Hopkins University](https://connect.biorxiv.org/group/content/47) * [Mathematical Oncology](https://connect.biorxiv.org/relate/content/1) * [Micron Oxford](https://connect.biorxiv.org/relate/content/116) * [Michigan State University](https://connect.biorxiv.org/group/content/7) * [Morgridge Institute](https://connect.biorxiv.org/group/content/57) * [National Taiwan University](https://connect.biorxiv.org/group/content/39) * [NCI Cancer Systems Biology Consortium](https://connect.biorxiv.org/relate/content/210) * [NF Open Science Initiative](https://connect.biorxiv.org/relate/content/213) * [NCI Human Tumor Atlas Network](https://connect.biorxiv.org/relate/content/171) * [Neuromatch Conference](https://connect.biorxiv.org/relate/content/209) * [NeurotechEU](https://connect.biorxiv.org/relate/content/189) * [North Carolina State University](https://connect.biorxiv.org/group/content/37) * [Northeastern University](https://connect.biorxiv.org/group/content/54) * [Oregon Health & Sciences University](https://connect.biorxiv.org/group/content/22) * [RNA Therapeutics Institute at UMass Chan Med School](https://connect.biorxiv.org/relate/content/243) * [Rosetta Commons](https://connect.biorxiv.org/relate/content/191) * [Rutgers University](https://connect.biorxiv.org/group/content/31) * [SeroNet](https://connect.biorxiv.org/relate/content/192) * [Simons Foundation Autism Research Initiative (SFARI)](https://connect.biorxiv.org/relate/content/74) * [Society for Molecular Biology and Evolution #SMBE2016](https://connect.biorxiv.org/relate/content/29) * [Somatic Cell Genome Editing Program](https://connect.biorxiv.org/relate/content/167) * [Somatic Mosaicism across the Human Tissues Network](https://connect.biorxiv.org/relate/content/222) * [SPARC](https://connect.biorxiv.org/relate/content/187) * [Stowers Institute for Medical Research](https://connect.biorxiv.org/group/content/3) * [Stockholm University](https://connect.biorxiv.org/group/content/14) * [Tel Aviv University](https://connect.biorxiv.org/group/content/8) * [The Michael J. Fox Foundation](https://connect.biorxiv.org/relate/content/207) * [The Rockefeller University](https://connect.biorxiv.org/group/content/2) * [The Sainsbury Laboratory](https://connect.biorxiv.org/relate/content/98) * [The Whitehead Institute](https://connect.biorxiv.org/relate/content/212) * [University of Connecticut Health Center](https://connect.biorxiv.org/group/content/16) * [University of California, Berkeley](https://connect.biorxiv.org/group/content/13) * [University of California, San Diego](https://connect.biorxiv.org/group/content/41) * [University of California, San Francisco](https://connect.biorxiv.org/group/content/10) * [University of Chicago](https://connect.biorxiv.org/group/content/42) * [University of Geneva](https://connect.biorxiv.org/group/content/26) * [University of Guelph](https://connect.biorxiv.org/group/content/23) * [University of Hong Kong](https://connect.biorxiv.org/group/content/29) * [University of Illinois Chicago](https://connect.biorxiv.org/group/content/43) * [University of Iowa](https://connect.biorxiv.org/group/content/24) * [University of Kansas](https://connect.biorxiv.org/group/content/33) * [University of Massachusetts Chan Medical School](https://connect.biorxiv.org/group/content/44) * [University of New South Wales](https://connect.biorxiv.org/group/content/25) * [University of Ottawa](https://connect.biorxiv.org/group/content/35) * [University of Sydney](https://connect.biorxiv.org/group/content/50) * [Vanderbilt University](https://connect.biorxiv.org/group/content/30) * [Vienna BioCenter](https://connect.biorxiv.org/relate/content/186) * [Washington University in St. Louis](https://connect.biorxiv.org/group/content/11) * [Weizmann Institute of Science](https://connect.biorxiv.org/group/content/15) * [Yale University](https://connect.biorxiv.org/group/content/53) Search for this keyword [Advanced Search](https://www.biorxiv.org/search) New Results Follow this preprint # A Three-Dimensional Bioprinted Skin Melanoma Model for High-Throughput Drug Screening [ View ORCID Profile](http://orcid.org/0000-0003-1655-3796)Paige J Derr, [ View ORCID Profile](http://orcid.org/0000-0003-0071-8664)Kristy Derr-Mierzwa, [ View ORCID Profile](http://orcid.org/0009-0002-0282-5463)Shayne Frebert, Min Shen, Ty Voss, [ View ORCID Profile](http://orcid.org/0000-0003-4569-9137)Marc Ferrer doi: https://doi.org/10.64898/2026.11.06.764888 This article is a preprint and has not been certified by peer review [[what does this mean?](https://www.biorxiv.org/about/FAQ#unrefereed)]. Paige J Derr NIH National Center for Advancing Translational Sciences * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Paige%2BJ%2BDerr%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=Derr%20PJ&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3APaige%2BJ%2BDerr%2B) * [ORCID record for Paige J Derr](http://orcid.org/0000-0003-1655-3796 "Open in new tab") * For correspondence: paige.derr@nih.gov Kristy Derr-Mierzwa NIH National Center for Advancing Translational Sciences * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Kristy%2BDerr-Mierzwa%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=Derr-Mierzwa%20K&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3AKristy%2BDerr-Mierzwa%2B) * [ORCID record for Kristy Derr-Mierzwa](http://orcid.org/0000-0003-0071-8664 "Open in new tab") Shayne Frebert NIH National Center for Advancing Translational Sciences * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Shayne%2BFrebert%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=Frebert%20S&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3AShayne%2BFrebert%2B) * [ORCID record for Shayne Frebert](http://orcid.org/0009-0002-0282-5463 "Open in new tab") Min Shen NIH National Center for Advancing Translational Sciences * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Min%2BShen%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=Shen%20M&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3AMin%2BShen%2B) Ty Voss NIH National Center for Advancing Translational Sciences * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Ty%2BVoss%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=Voss%20T&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3ATy%2BVoss%2B) Marc Ferrer NIH National Center for Advancing Translational Sciences * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Marc%2BFerrer%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=Ferrer%20M&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3AMarc%2BFerrer%2B) * [ORCID record for Marc Ferrer](http://orcid.org/0000-0003-4569-9137 "Open in new tab") * [Abstract](https://www.biorxiv.org/content/10.64898/2026.11.06.764888v1)[](https://www.biorxiv.org/panels_ajax_tab/biorxiv_tab_art/node:5964150/1) * [Info/History](https://www.biorxiv.org/content/10.64898/2026.11.06.764888v1.article-info)[](https://www.biorxiv.org/panels_ajax_tab/biorxiv_tab_info/node:5964150/1) * [Metrics](https://www.biorxiv.org/content/10.64898/2026.11.06.764888v1.article-metrics)[](https://www.biorxiv.org/panels_ajax_tab/article_tab_metrics/node:5964150/1) * [Supplementary material](https://www.biorxiv.org/content/10.64898/2026.11.06.764888v1.supplementary-material)[](https://www.biorxiv.org/panels_ajax_tab/biorxiv_tab_data/node:5964150/1) * [ Preview PDF](https://www.biorxiv.org/content/10.64898/2026.11.06.764888v1.full.pdf+html)[](https://www.biorxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:5964150/1) ![Loading](https://www.biorxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract Melanoma is the deadliest form of skin cancer, and despite major advances in immunotherapy and targeted therapies, most patients with advanced disease eventually develop treatment resistance. The lack of physiologically relevant, scalable preclinical models that recapitulate the tumor microenvironment (TME) remains a major barrier to identifying more effective therapies. Here, we present a novel high-throughput screening platform based on a bioprinted, full-thickness human melanoma skin model that combines the biological complexity of native skin with the scalability required for drug discovery. The 3D tissue construct comprises a dermal region containing primary human dermal fibroblasts, melanoma tumor-like cell clusters localized at the dermal-epidermal interface, and an overlying differentiated epidermis composed of primary human keratinocytes cultured at the air-liquid interface, thereby recapitulating key structural and cellular features of the melanoma TME. To enable multiplexed, high-content analysis, melanoma cells and fibroblasts were engineered to express red and green fluorescent proteins, respectively, allowing automated confocal imaging to simultaneously quantify tumor growth and stromal viability. This dual-readout strategy provides an intrinsic counterscreen to distinguish melanoma-selective compounds from nonspecific cytotoxic agents. The assay was implemented in a 96-well bioprinted format compatible with high-throughput screening of compound libraries across multiple concentrations. Using this platform, we identified compounds that selectively reduced melanoma cell viability while sparing surrounding stromal cells, demonstrating the value of incorporating the TME into primary drug screens. By integrating bioprinting, human tissue engineering, and automated high-content imaging into a scalable workflow, this platform provides a robust and clinically relevant approach for melanoma therapeutic discovery and has the potential to improve the translation of preclinical findings into effective treatments for advanced melanoma. ### Competing Interest Statement The authors have declared no competing interest. ## Funder Information Declared Cures Acceleration Network at NCATS NIH Intramural Research Program Copyright The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/). bioRxiv and medRxiv thank the following for their generous financial support: > The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. [Donate to openRxiv ](https://www.zeffy.com/en-US/donation-form/donate-to-make-a-difference-10981) [ Back to top](https://www.biorxiv.org/content/10.64898/2026.11.06.764888v1?rss=1#page) [ Previous](https://www.biorxiv.org/content/10.64898/2026.11.10.762907v1 "An expanded, phenotypically distinct tumor cell subset with low HPV mRNA increases recurrence risk")[Next ](https://www.biorxiv.org/content/10.64898/2026.11.13.766243v1 "Temporally Dynamic Waves of Selection on Archaic Variation in Peruvians") Posted November 14, 2026. [ Download PDF](https://www.biorxiv.org/content/10.64898/2026.11.06.764888v1.full.pdf) Print/Save Options [Download PDF](https://www.biorxiv.org/content/biorxiv/early/2026/11/14/2026.11.06.764888.full.pdf)Full Text & In-line FiguresXML [More Info](https://www.biorxiv.org/about/FAQ#PrintOptions "More Information on Print/Save Options") [Supplementary Material ](https://www.biorxiv.org/content/10.64898/2026.11.06.764888v1.supplementary-material) [ Email](https://www.biorxiv.org/ "Email this Article") [ Share](https://www.biorxiv.org/) A Three-Dimensional Bioprinted Skin Melanoma Model for High-Throughput Drug Screening Paige J Derr, Kristy Derr-Mierzwa, Shayne Frebert, Min Shen, Ty Voss, Marc Ferrer bioRxiv 2026.11.06.764888; doi: https://doi.org/10.64898/2026.11.06.764888 This article is a preprint and has not been certified by peer review [[what does this mean?](https://www.biorxiv.org/about/FAQ#unrefereed)]. Share This Article: Copy [![Twitter logo](https://www.biorxiv.org/sites/all/modules/highwire/highwire/images/twitter.png)](https://www.biorxiv.org/highwire_log/share/twitter?link=http%3A%2F%2Ftwitter.com%2Fshare%3Furl%3Dhttps%253A%2F%2Fwww.biorxiv.org%2Fcontent%2F10.64898%2F2026.11.06.764888v1%26text%3DA%2520Three-Dimensional%2520Bioprinted%2520Skin%2520Melanoma%2520Model%2520for%2520High-Throughput%2520Drug%2520Screening "Share this on Twitter") [![Facebook logo](https://www.biorxiv.org/sites/all/modules/highwire/highwire/images/fb-blue.png)](https://www.biorxiv.org/highwire_log/share/facebook?link=http%3A%2F%2Fwww.facebook.com%2Fsharer.php%3Fu%3Dhttps%253A%2F%2Fwww.biorxiv.org%2Fcontent%2F10.64898%2F2026.11.06.764888v1%26t%3DA%2520Three-Dimensional%2520Bioprinted%2520Skin%2520Melanoma%2520Model%2520for%2520High-Throughput%2520Drug%2520Screening "Share on Facebook") [![LinkedIn logo](https://www.biorxiv.org/sites/all/modules/highwire/highwire/images/linkedin-32px.png)](https://www.biorxiv.org/highwire_log/share/linkedin?link=http%3A%2F%2Fwww.linkedin.com%2FshareArticle%3Fmini%3Dtrue%26url%3Dhttps%253A%2F%2Fwww.biorxiv.org%2Fcontent%2F10.64898%2F2026.11.06.764888v1%26title%3DA%2520Three-Dimensional%2520Bioprinted%2520Skin%2520Melanoma%2520Model%2520for%2520High-Throughput%2520Drug%2520Screening%26summary%3D%26source%3DbioRxiv "Publish this post to LinkedIn") [![Mendeley logo](https://www.biorxiv.org/sites/all/modules/highwire/highwire/images/mendeley.png)](https://www.biorxiv.org/highwire_log/share/mendeley?link=http%3A%2F%2Fwww.mendeley.com%2Fimport%2F%3Furl%3Dhttps%253A%2F%2Fwww.biorxiv.org%2Fcontent%2F10.64898%2F2026.11.06.764888v1%26title%3DA%2520Three-Dimensional%2520Bioprinted%2520Skin%2520Melanoma%2520Model%2520for%2520High-Throughput%2520Drug%2520Screening "Share on Mendeley") [ Citation Tools](https://www.biorxiv.org/ "Citation Tools") [ Get QR code](https://connect.biorxiv.org/qr/2026.11.06.764888) * [Tweet Widget](http://twitter.com/share?url=https%3A//www.biorxiv.org/con
## Related Clinical Research

- [Continuous karyotypic instability and structural flux in acral melanoma genomes](https://medichelpline.com/clinical-feed/biorxiv-0-continuous-karyotypic-and-cryptic-structural-fluctuations-drive-acral-melanoma.md)
- [LATS1 as a context-specific regulator in melanoma: preprint reports a zebrafish lats1 knockout mod](https://medichelpline.com/clinical-feed/biorxiv-0-integrative-analysis-identifies-lats1-as-a-context-specific-regulator-of.md)
- [Dual immune checkpoint inhibition for melanoma brain metastases: safety and efficacy meta-analysis](https://medichelpline.com/clinical-feed/pubmed-42934318.md) (DOI: 10.1007/s10143-026-04538-w)
- [State Tanning Bed Availability Linked to Higher Early-Onset Melanoma in Midwest and South](https://medichelpline.com/clinical-feed/medrxiv-1-state-tanning-bed-availability-is-associated-with-early-onset-melanoma.md)
- [Personalized mRNA vaccine plus pembrolizumab lowers melanoma recurrence in phase 3 trial](https://medichelpline.com/clinical-feed/medical-news-today-0-novel-mrna-vaccine-plus-immunotherapy-reduces-melanoma-relapse-in-phase-3-trial.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.